A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.

Source:http://linkedlifedata.com/resource/pubmed/id/17145827

Clin. Cancer Res. 2006 Dec 1 12 23 7046-53

Download in:

View as

Triples

General Info

PMID
17145827